Shares of MAP Pharmaceuticals skyrocketed today, up nearly 60% on the news that the company was being acquired by its marketing partner Allergan for the premium of $25 per share. In this video, Motley Fool health-care analyst David Williamson tells us some of the unexpected synergies that Allergan, the company behind Botox, will be looking for in MAP Pharmaceuticals, and why this might be a good fit.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article MAP Investors: X Marks the Buyout originally appeared on Fool.com.David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.